Rep. Bruce Westerman Buys GSK plc (NYSE:GSK) Shares

Representative Bruce Westerman (R-Arkansas) recently bought shares of GSK plc (NYSE:GSK). In a filing disclosed on April 16th, the Representative disclosed that they had bought between $1,001 and $15,000 in GSK stock on March 3rd. The trade occurred in the Representative’s “FISHER IRA” account.

Representative Bruce Westerman also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of LVMH Moët Hennessy – Louis Vuitton, Société Européenne (OTCMKTS:LVMUY) on 4/2/2025.
• Purchased $1,001 – $15,000 in shares of Sony Group (NYSE:SONY) on 3/24/2025.
• Purchased $1,001 – $15,000 in shares of Mitsubishi UFJ Financial Group (NYSE:MUFG) on 3/21/2025.
• Purchased $1,001 – $15,000 in shares of BP (NYSE:BP) on 3/21/2025.
• Sold $1,001 – $15,000 in shares of Procter & Gamble (NYSE:PG) on 3/20/2025.
• Sold $1,001 – $15,000 in shares of Medtronic (NYSE:MDT) on 3/20/2025.
• Purchased $1,001 – $15,000 in shares of ASML (NASDAQ:ASML) on 3/20/2025.
• Sold $1,001 – $15,000 in shares of Visa (NYSE:V) on 3/20/2025.
• Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 3/20/2025.
• Sold $1,001 – $15,000 in shares of Broadcom (NASDAQ:AVGO) on 3/20/2025.

GSK Stock Up 1.5 %

GSK stock traded up $0.55 during trading on Friday, hitting $35.92. 4,812,738 shares of the stock traded hands, compared to its average volume of 4,650,435. The stock has a market cap of $74.10 billion, a price-to-earnings ratio of 22.59, a price-to-earnings-growth ratio of 1.12 and a beta of 0.56. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52. GSK plc has a 1 year low of $31.72 and a 1 year high of $45.93. The firm’s 50 day moving average is $37.44 and its two-hundred day moving average is $36.14.

GSK (NYSE:GSK) last posted its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. On average, sell-side analysts anticipate that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, April 10th. Stockholders of record on Friday, February 21st were given a $0.3932 dividend. The ex-dividend date was Friday, February 21st. This is an increase from GSK’s previous quarterly dividend of $0.39. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.38%. GSK’s dividend payout ratio is currently 100.63%.

Wall Street Analysts Forecast Growth

GSK has been the topic of several research reports. BNP Paribas initiated coverage on GSK in a research report on Tuesday. They issued a “neutral” rating and a $35.25 target price on the stock. Morgan Stanley initiated coverage on shares of GSK in a report on Wednesday, February 12th. They set an “equal weight” rating for the company. Finally, StockNews.com cut shares of GSK from a “strong-buy” rating to a “buy” rating in a research note on Wednesday. Eight investment analysts have rated the stock with a hold rating, one has assigned a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, GSK has an average rating of “Moderate Buy” and a consensus target price of $40.58.

Hedge Funds Weigh In On GSK

Institutional investors have recently added to or reduced their stakes in the stock. Indiana Trust & Investment Management Co increased its stake in GSK by 200.0% during the 4th quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company’s stock worth $25,000 after buying an additional 500 shares during the period. Crews Bank & Trust purchased a new stake in GSK in the 4th quarter valued at approximately $26,000. ST Germain D J Co. Inc. increased its holdings in GSK by 195.5% in the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock valued at $27,000 after buying an additional 522 shares in the last quarter. Sierra Ocean LLC purchased a new stake in shares of GSK in the fourth quarter valued at about $32,000. Finally, Parkside Financial Bank & Trust boosted its stake in shares of GSK by 470.1% during the 4th quarter. Parkside Financial Bank & Trust now owns 992 shares of the pharmaceutical company’s stock worth $34,000 after purchasing an additional 818 shares during the last quarter. Hedge funds and other institutional investors own 15.74% of the company’s stock.

About Representative Westerman

Bruce Westerman (Republican Party) is a member of the U.S. House, representing Arkansas’ 4th Congressional District. He assumed office on January 3, 2015. His current term ends on January 3, 2027.

Westerman (Republican Party) is running for re-election to the U.S. House to represent Arkansas’ 4th Congressional District. He declared candidacy for the 2026 election.

Westerman earned his BSBAGE in biological and agricultural engineering from the University of Arkansas in 1990 and his MF in forestry from Yale University in 2001. His professional experience includes working as a plant engineer for Riceland Foods and an engineer/forester for Mid-South Engineering Company.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.